Type 1 diabetes patients who received high-dose insulin degludec once daily showed lower rates of nocturnal hypoglycemia than their counterparts who took insulin glargine, a study showed. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.
Degludec outperforms glargine in curbing nocturnal hypoglycemia
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan